MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals, Inc. (MDGL: Nasdaq) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for metabolic dysfunction-associated steatohepatitis, a serious liver disease characterized by inflammation, cellular damage, and fibrosis that can progress to cirrhosis, liver… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MADRIGAL PHARMACEUTICALS, INC. does
In the company’s own words
Madrigal Pharmaceuticals, Inc. (MDGL: Nasdaq) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for metabolic dysfunction-associated steatohepatitis, a serious liver disease characterized by inflammation, cellular damage, and fibrosis that can progress to cirrhosis, liver failure, and liver cancer. The company's website is www.madrigalpharma.com.
Madrigal's primary product is Rezdiffra (resmetirom), a once-daily oral liver-directed thyroid hormone receptor beta agonist approved by the FDA in March 2024 for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The European Commission granted conditional marketing authorization in August 2025, making Rezdiffra the first medication approved by both regulatory bodies for this indication. The company launched Rezdiffra in the United States in April 2024 and in Germany in September 2025, generating $958.4 million in product revenue during 2025.
Beyond its approved therapy, Madrigal is building a focused pipeline to establish industry leadership in MASH treatment. The company has acquired rights to MGL-2086, an oral glucagon-like peptide-1 receptor agonist; ervogastat, an oral DGAT2 inhibitor; and six small interfering RNA programs designed to target genes implicated in MASH disease progression. These candidates are being evaluated for potential combination therapy with Rezdiffra to enhance efficacy across the MASH spectrum.
The company is advancing two significant clinical trials to expand Rezdiffra's market opportunity. The MAESTRO-NASH OUTCOMES trial, which completed enrollment of 845 patients, is evaluating Rezdiffra in patients with compensated MASH cirrhosis, with results expected in 2027. Positive outcomes could potentially double Rezdiffra's commercial opportunity by supporting approval in this patient population with no currently available treatments. Additionally, the company expects outcomes data from its MAESTRO-NASH trial in 2028 to support full FDA approval.
Madrigal operates under an exclusive worldwide license agreement with Hoffmann-La Roche for resmetirom development and commercialization rights. The company secured $350 million in senior secured financing in July 2025 with access to additional delayed draw and incremental facilities totaling up to $400 million.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WEST CONSHOHOCKEN, PA
- Fiscal year end
- December
- CIK
- 1157601
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MADRIGAL PHARMACEUTICALS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MADRIGAL PHARMACEUTICALS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MADRIGAL PHARMACEUTICALS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MADRIGAL PHARMACEUTICALS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MADRIGAL PHARMACEUTICALS, INC.'s last four quarterly filings that the numbers alone won't show?”